Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038880 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
A Phase 2 study of Macular Degeneration, Age-related and Neovascularization, Choroidal, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT03038880 is a Phase 2 study of Macular Degeneration, Age-related and Neovascularization, Choroidal that has completed, run by Hoffmann-La Roche. The registered enrollment target is 76 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03038880, a Phase 2 study of Macular Degeneration, Age-related and Neovascularization, Choroidal, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.
Conditions Studied
Interventions
- DRUG Faricimab
- DRUG Ranibizumab
- DRUG Sham Procedure
Study Locations (20)
Florida
- Rand Eye - Deerfield Beach
- Florida Eye Associates - Melbourne
- Retina Vitreous Assoc of FL - St. Petersburg
- Southern Vitreoretinal Assoc - Tallahassee
Arizona
- Retinal Consultants of Arizona - Phoenix
- Retina Associates Southwest PC - Tucson
California
- California Retina Consultants - Bakersfield
- Retinal Diagnostic Center - Campbell
Oregon
- Oregon Retina, LLP - Eugene
- Retina Northwest - Portland
Colorado
- Retina Consultants of Southern Colorado PC; Clinical Research Department - Colorado Springs
Georgia
- Southeast Retina Center - Augusta
Indiana
- Midwest Eye Institute - Indianapolis
Iowa
- Wolfe Eye Clinic - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038880
The ClinicalTrials.gov registry entry for NCT03038880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Degeneration, Age-related appearing as the primary indexed condition, and to 3 interventions - of which Faricimab is the first listed.
NCT03038880 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03038880 about?
NCT03038880 is a clinical study titled "Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration". This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degenera...
What is the current status of trial NCT03038880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2017-01-27. Estimated completion is 2018-03-29.
What conditions does trial NCT03038880 study?
This clinical trial studies the following conditions: Macular Degeneration, Age-related, Neovascularization, Choroidal.
What interventions are being tested in trial NCT03038880?
The interventions under investigation include: Faricimab (DRUG), Ranibizumab (DRUG), Sham Procedure (DRUG).
Who is sponsoring clinical trial NCT03038880?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03038880 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration, Age-related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Macular Degeneration, Age-related
All registered trials for this condition
Neovascularization, Choroidal
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.